JP2019527039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527039A5 JP2019527039A5 JP2018565368A JP2018565368A JP2019527039A5 JP 2019527039 A5 JP2019527039 A5 JP 2019527039A5 JP 2018565368 A JP2018565368 A JP 2018565368A JP 2018565368 A JP2018565368 A JP 2018565368A JP 2019527039 A5 JP2019527039 A5 JP 2019527039A5
- Authority
- JP
- Japan
- Prior art keywords
- ibd
- expression
- genes
- gene
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 claims description 48
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 33
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 18
- 102100038393 Granzyme H Human genes 0.000 claims description 18
- 102100028539 Guanylate-binding protein 5 Human genes 0.000 claims description 18
- 102000018671 Lymphocyte Antigen 96 Human genes 0.000 claims description 18
- 108010066789 Lymphocyte Antigen 96 Proteins 0.000 claims description 18
- 102100022571 T cell receptor gamma constant 2 Human genes 0.000 claims description 18
- 102100022591 T cell receptor gamma variable 3 Human genes 0.000 claims description 18
- 101000784133 Homo sapiens Arrestin domain-containing protein 4 Proteins 0.000 claims description 17
- 101000595347 Homo sapiens Peroxisomal coenzyme A diphosphatase NUDT7 Proteins 0.000 claims description 17
- 101000679305 Homo sapiens T cell receptor gamma variable 3 Proteins 0.000 claims description 17
- 102100036024 Peroxisomal coenzyme A diphosphatase NUDT7 Human genes 0.000 claims description 17
- 101001004750 Homo sapiens Galectin-related protein Proteins 0.000 claims description 16
- 102100025614 Galectin-related protein Human genes 0.000 claims description 12
- 102100021038 Arrestin domain-containing protein 4 Human genes 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 238000007477 logistic regression Methods 0.000 claims description 2
- 102000001398 Granzyme Human genes 0.000 claims 16
- 108060005986 Granzyme Proteins 0.000 claims 16
- 101710113220 Granzyme H Proteins 0.000 claims 16
- 101710110795 Guanylate-binding protein 5 Proteins 0.000 claims 16
- 102000014702 Haptoglobin Human genes 0.000 claims 16
- 108050005077 Haptoglobin Proteins 0.000 claims 16
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims 16
- 108010058010 Interleukin-18 Receptor beta Subunit Proteins 0.000 claims 16
- 102000006253 Interleukin-18 Receptor beta Subunit Human genes 0.000 claims 16
- 101710081120 T cell receptor gamma constant 2 Proteins 0.000 claims 16
- 239000000523 sample Substances 0.000 claims 11
- 238000011529 RT qPCR Methods 0.000 claims 10
- 238000012163 sequencing technique Methods 0.000 claims 9
- 239000000126 substance Substances 0.000 claims 9
- 238000011282 treatment Methods 0.000 claims 8
- 239000002299 complementary DNA Substances 0.000 claims 7
- 238000007847 digital PCR Methods 0.000 claims 7
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims 6
- 239000003018 immunosuppressive agent Substances 0.000 claims 6
- 229940125721 immunosuppressive agent Drugs 0.000 claims 6
- 230000001105 regulatory effect Effects 0.000 claims 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims 4
- 238000010195 expression analysis Methods 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 238000010208 microarray analysis Methods 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 108091006027 G proteins Proteins 0.000 claims 1
- 102000030782 GTP binding Human genes 0.000 claims 1
- 108091000058 GTP-Binding Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102100037601 P2X purinoceptor 4 Human genes 0.000 claims 1
- 108010080192 Purinergic Receptors Proteins 0.000 claims 1
- 101710151315 T cell receptor gamma variable 3 Proteins 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000001177 diphosphate Substances 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000012502 risk assessment Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000003827 upregulation Effects 0.000 claims 1
- -1 VTRNA1-1 Proteins 0.000 description 4
- 101150032879 Fcrl5 gene Proteins 0.000 description 2
- 102100038395 Granzyme K Human genes 0.000 description 2
- 101001033000 Homo sapiens Granzyme H Proteins 0.000 description 2
- 101001033007 Homo sapiens Granzyme K Proteins 0.000 description 2
- 101001058850 Homo sapiens Guanylate-binding protein 5 Proteins 0.000 description 2
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 description 2
- 101001019615 Homo sapiens Interleukin-18 receptor accessory protein Proteins 0.000 description 2
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 2
- 101001121539 Homo sapiens P2Y purinoceptor 14 Proteins 0.000 description 2
- 101000679307 Homo sapiens T cell receptor gamma constant 2 Proteins 0.000 description 2
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 description 2
- 102100035010 Interleukin-18 receptor accessory protein Human genes 0.000 description 2
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 2
- 102100025808 P2Y purinoceptor 14 Human genes 0.000 description 2
- 201000008638 inflammatory bowel disease 1 Diseases 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1611738.4A GB201611738D0 (en) | 2016-07-05 | 2016-07-05 | Biomarkers for inflammatory bowel disease |
| GB1611738.4 | 2016-07-05 | ||
| PCT/IB2017/000997 WO2018007872A1 (en) | 2016-07-05 | 2017-07-05 | Biomarkers for inflammatory bowel disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020136564A Division JP2020198884A (ja) | 2016-07-05 | 2020-08-13 | 炎症性腸疾患用のバイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527039A JP2019527039A (ja) | 2019-09-26 |
| JP2019527039A5 true JP2019527039A5 (enExample) | 2019-11-28 |
| JP7111630B2 JP7111630B2 (ja) | 2022-08-02 |
Family
ID=56891052
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565368A Active JP7111630B2 (ja) | 2016-07-05 | 2017-07-05 | 炎症性腸疾患用のバイオマーカー |
| JP2020136564A Pending JP2020198884A (ja) | 2016-07-05 | 2020-08-13 | 炎症性腸疾患用のバイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020136564A Pending JP2020198884A (ja) | 2016-07-05 | 2020-08-13 | 炎症性腸疾患用のバイオマーカー |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11041206B2 (enExample) |
| EP (1) | EP3481964B1 (enExample) |
| JP (2) | JP7111630B2 (enExample) |
| KR (1) | KR102352847B1 (enExample) |
| CN (1) | CN109477145B (enExample) |
| AU (1) | AU2017293417B2 (enExample) |
| CA (1) | CA3029912A1 (enExample) |
| DK (1) | DK3481964T3 (enExample) |
| ES (1) | ES2906192T3 (enExample) |
| GB (1) | GB201611738D0 (enExample) |
| HU (1) | HUE058197T2 (enExample) |
| LT (1) | LT3481964T (enExample) |
| PL (1) | PL3481964T3 (enExample) |
| PT (1) | PT3481964T (enExample) |
| WO (1) | WO2018007872A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10515408B2 (en) | 2003-08-13 | 2019-12-24 | Bgc Partners, Inc. | Systems and methods for bid/offer liquidity spread trading |
| GB201611738D0 (en) | 2016-07-05 | 2016-08-17 | Cambridge Entpr Ltd | Biomarkers for inflammatory bowel disease |
| CA3047302C (en) * | 2016-12-14 | 2024-01-02 | Tracy WARREN | System and methods for developing and using a microbiome-based action component for patient health |
| US11978543B2 (en) | 2016-12-14 | 2024-05-07 | Astarte Medical Partners Inc. | System and methods for developing and using a microbiome-based action component |
| EP3866920B1 (en) | 2018-10-18 | 2025-12-10 | T.J.Smith And Nephew, Limited | Tissue treatment device |
| GB201817052D0 (en) | 2018-10-19 | 2018-12-05 | Smith & Nephew | Tissue treatment device |
| CN110400603A (zh) * | 2019-07-23 | 2019-11-01 | 中国石油大学(华东) | 基于格局加权的ibd矩阵计算方法 |
| GB201912518D0 (en) | 2019-08-30 | 2019-10-16 | Cambridge Entpr Ltd | Inflammatory disease prognostics |
| GB202005867D0 (en) | 2020-04-22 | 2020-06-03 | Smith & Nephew | Tissue treatment device |
| GB202100527D0 (en) | 2021-01-15 | 2021-03-03 | Smith & Nephew | Systems and methods for managing operation of wound dressings or wound treatment devices |
| WO2022190036A2 (en) * | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Methods for predicting treatment response in ulcerative colitis |
| CN114517228A (zh) * | 2021-12-31 | 2022-05-20 | 青岛锐翌精准医学检验有限公司 | 炎症性肠病标志基因及其应用 |
| CN114645088B (zh) * | 2022-04-22 | 2023-12-15 | 广东省人民医院 | 克罗恩病进展风险相关评估基因集、试剂盒、应用和系统 |
| EP4606910A1 (en) * | 2024-02-21 | 2025-08-27 | Royal College of Surgeons in Ireland | Diagnostic and prognostic methods relating to ulcerative colitis |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0412301D0 (en) | 2004-06-02 | 2004-07-07 | Diagenic As | Product and method |
| EP1888789A2 (en) * | 2005-06-06 | 2008-02-20 | Wyeth a Corporation of the State of Delaware | Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases |
| GB0610949D0 (en) * | 2006-06-02 | 2006-07-12 | Glaxosmithkline Biolog Sa | Method |
| MX2010005893A (es) * | 2007-11-29 | 2011-03-04 | Genentech Inc Star | Marcadores de expresion genica para enfermedad inflamatoria de intestino. |
| US20100222262A1 (en) * | 2008-04-02 | 2010-09-02 | Metaproteomics, Llc | Substituted 1, 3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions |
| KR100985090B1 (ko) * | 2008-05-23 | 2010-10-04 | 한국과학기술연구원 | 크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법 |
| US20120003228A1 (en) * | 2009-01-20 | 2012-01-05 | Cambridge Enterprise Limited | Methods for predicting autoimmune disease risk |
| EP2419532A1 (en) * | 2009-04-17 | 2012-02-22 | Université Libre de Bruxelles | Methods and tools for predicting the efficiency of anthracyclines in cancer |
| EP2272977A1 (en) | 2009-07-08 | 2011-01-12 | Universite Libre De Bruxelles | Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome |
| CA2795776A1 (en) * | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| CA2827894A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| WO2012154987A1 (en) | 2011-05-10 | 2012-11-15 | Nestec Sa | Methods of disease activity profiling for personalized therapy management |
| KR20140097336A (ko) * | 2011-11-23 | 2014-08-06 | 암젠 인크 | 인터페론 감마에 대한 항체를 이용한 치료 방법 |
| WO2013138497A1 (en) | 2012-03-13 | 2013-09-19 | Baylor Research Institute | Early detection of tuberculosis treatment response |
| MX358730B (es) | 2012-10-05 | 2018-09-03 | Nestec Sa | Metodos para predecir y monitorear cicatrizacion de la mucosa. |
| EP2931923A1 (en) | 2012-12-13 | 2015-10-21 | Baylor Research Institute | Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis |
| CN105683392A (zh) * | 2013-03-15 | 2016-06-15 | 博德研究所 | 树突细胞应答基因表达、物质组合物及其使用方法 |
| US10619210B2 (en) * | 2014-02-07 | 2020-04-14 | The Johns Hopkins University | Predicting response to epigenetic drug therapy |
| MA39804A (fr) * | 2014-03-27 | 2017-02-01 | Hoffmann La Roche | Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin |
| US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| WO2016066288A1 (en) | 2014-10-28 | 2016-05-06 | Comprehensive Biomarker Center Gmbh | Mirnas as non-invasive biomarkers for inflammatory bowel disease |
| EP3262193A2 (en) * | 2015-02-26 | 2018-01-03 | The Broad Institute Inc. | T cell balance gene expression, compositions of matters and methods of use thereof |
| JP2018512876A (ja) | 2015-04-22 | 2018-05-24 | ミナ セラピューティクス リミテッド | ｓａＲＮＡ組成物および使用方法 |
| US20170003277A1 (en) * | 2015-07-01 | 2017-01-05 | Michael Hayden | Biological characterization of a glatiramer acetate related drug product using mammalian and human cells |
| GB201611738D0 (en) | 2016-07-05 | 2016-08-17 | Cambridge Entpr Ltd | Biomarkers for inflammatory bowel disease |
-
2016
- 2016-07-05 GB GBGB1611738.4A patent/GB201611738D0/en not_active Ceased
-
2017
- 2017-07-05 JP JP2018565368A patent/JP7111630B2/ja active Active
- 2017-07-05 LT LTEPPCT/IB2017/000997T patent/LT3481964T/lt unknown
- 2017-07-05 AU AU2017293417A patent/AU2017293417B2/en not_active Ceased
- 2017-07-05 WO PCT/IB2017/000997 patent/WO2018007872A1/en not_active Ceased
- 2017-07-05 US US15/642,252 patent/US11041206B2/en not_active Expired - Fee Related
- 2017-07-05 HU HUE17768220A patent/HUE058197T2/hu unknown
- 2017-07-05 EP EP17768220.0A patent/EP3481964B1/en active Active
- 2017-07-05 KR KR1020197002309A patent/KR102352847B1/ko not_active Expired - Fee Related
- 2017-07-05 CN CN201780041664.4A patent/CN109477145B/zh not_active Expired - Fee Related
- 2017-07-05 PL PL17768220T patent/PL3481964T3/pl unknown
- 2017-07-05 ES ES17768220T patent/ES2906192T3/es active Active
- 2017-07-05 PT PT177682200T patent/PT3481964T/pt unknown
- 2017-07-05 CA CA3029912A patent/CA3029912A1/en active Pending
- 2017-07-05 DK DK17768220.0T patent/DK3481964T3/da active
- 2017-07-17 US US15/651,746 patent/US10202651B2/en active Active
-
2018
- 2018-10-12 US US16/159,114 patent/US10640829B2/en active Active
-
2020
- 2020-08-13 JP JP2020136564A patent/JP2020198884A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527039A5 (enExample) | ||
| JP6931125B2 (ja) | 標的遺伝子発現の数学的モデル化を使用する、ｊａｋ−ｓｔａｔ１／２細胞シグナル伝達経路活性の評価 | |
| JP6415712B2 (ja) | 標的遺伝子発現の数学的モデル化を用いるＴＧＦ−β細胞シグナル伝達経路活性の評価 | |
| Lin et al. | Genome-wide microarray analysis of gene expression profiling in major depression and antidepressant therapy | |
| RU2766004C1 (ru) | Способ оценки нормального состояния иммунного репертуара и его применение | |
| JP6280206B2 (ja) | 局所進行性胃癌に対する予後予測システム | |
| JP2019076096A (ja) | 目的遺伝子発現の線形結合を用いた細胞信号伝達経路活性の評価 | |
| JP2016525355A5 (enExample) | ||
| JP2018531044A6 (ja) | 免疫レパートリーの正常性の評価方法およびその使用 | |
| CN109477145A (zh) | 炎症性肠病的生物标志物 | |
| JP6864089B2 (ja) | 進行性胃癌患者の手術後の予後または抗癌剤適合性予測システム | |
| CA2824854A1 (en) | Immunodiversity assessment method and its use | |
| JP2016506750A5 (enExample) | ||
| Ren et al. | Gene expression profiling of humans under exertional heat stress: Comparisons between persons with and without exertional heat stroke | |
| JP2024526977A (ja) | 免疫療法後の治療反応のためのバイオマーカー | |
| CN105506083B (zh) | Capg在制备诊断帕金森症产品中的用途 | |
| JP6974181B2 (ja) | 個体の免疫レパートリーの変化を測定するための方法 | |
| US20170145501A1 (en) | Apparatus and methods of using of biomarkers for predicting tnf-inhibitor response | |
| WO2019025624A1 (en) | BIOMARKERS FOR ASSESSING STATUS OF RESPONSE TO TREATMENT OF INFLAMMATORY CONDITION OR DISEASE AFFECTING THE DIGESTIVE TUBE AS AN INFLAMMATORY BOWEL DISEASE IN HUMAN PATIENTS | |
| Shao et al. | High-throughput sequencing reveals the diversity of TCR β chain CDR3 repertoire in patients with severe acne | |
| Ghannam et al. | Noninvasive stool RNA test approximates disease activity in patients with Crohn’s Disease | |
| Lambrechts et al. | Gene markers in dendritic cells unravel pieces of the skin sensitization puzzle | |
| JP6612509B2 (ja) | 大腸癌の予後診断を補助する方法、記録媒体および判定装置 | |
| JP2023515952A (ja) | 免疫チェックポイント遮断治療での処置を改善するための方法 | |
| Hiyoshi-Kanemoto et al. | Detection of circulating tumor cells using GeneScan analysis for antigen receptor gene rearrangements in canine lymphoma patients |